» Articles » PMID: 8346953

Pulmonary Inflammatory Cells in Ventilated Preterm Infants: Effect of Surfactant Treatment

Overview
Journal Arch Dis Child
Specialty Pediatrics
Date 1993 Jul 1
PMID 8346953
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to determine the effect of surfactant treatment on the number and distribution of inflammatory cells in bronchoalveolar lavage fluid (BALF) from mechanically ventilated preterm infants over the first week of life in relation to the subsequent development of chronic lung disease (CLD). The study included 25 babies who received surfactant on clinical grounds and 29 babies of similar severity who did not. BALF was collected on days 1, 3, 5, and 7 after birth. Cell counts were performed and differentials were calculated on 300 cells. CLD was equally common in both treatment groups. Of the 54 infants, 29 (53%) who developed CLD had a higher incidence of patent ductus arteriosus and air leak and needed a higher concentration of inspired oxygen on the fifth and seventh days of life. Babies who developed CLD had more polymorphonuclear leucocytes and fewer macrophages on days 5 and 7 than those who recovered. Surfactant treatment was associated with a higher total white cell count on day 3. Between days 3 and 7, macrophage numbers were higher in surfactant treated babies, whatever the pulmonary outcome. This data suggests that CLD was associated with persistence of high numbers of polymorphonuclear leucocytes in BALF at the end of the first week. Surfactant treatment caused a persistent increase in macrophage numbers. The association between persistent neutrophilia and CLD was unaffected by surfactant treatment.

Citing Articles

Anti-CCL2 therapy reduces oxygen toxicity to the immature lung.

Shahzad T, Dong Y, Behnke N, Brandner J, Hilgendorff A, Chao C Cell Death Discov. 2024; 10(1):311.

PMID: 38961074 PMC: 11222519. DOI: 10.1038/s41420-024-02073-5.


Serum eotaxin-1 is increased in extremely-low-birth-weight infants with bronchopulmonary dysplasia or death.

Kandasamy J, Roane C, Szalai A, Ambalavanan N Pediatr Res. 2015; 78(5):498-504.

PMID: 26270578 PMC: 4628573. DOI: 10.1038/pr.2015.152.


Mechanisms of bronchopulmonary dysplasia.

Popova A J Cell Commun Signal. 2013; 7(2):119-27.

PMID: 23334556 PMC: 3660689. DOI: 10.1007/s12079-013-0190-x.


Elastase inhibitory activity of airway α1-antitrypsin is protected by treatment with a catalytic antioxidant in a baboon model of severe bronchopulmonary dysplasia.

Karaaslan C, Hirakawa H, Yasumatsu R, Chang L, Pierce R, Crapo J Pediatr Res. 2011; 70(4):363-7.

PMID: 21705962 PMC: 3166355. DOI: 10.1203/PDR.0b013e31822a357e.


Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Hassan H, Othman A, Eddington N, Duffy L, Xiao L, Waites K J Clin Pharmacol. 2010; 51(9):1264-75.

PMID: 21098694 PMC: 4240745. DOI: 10.1177/0091270010382021.


References
1.
Sieger L . Pulmonary alveolar macrophages in pre- and post-natal rabbits. J Reticuloendothel Soc. 1978; 23(5):389-95. View

2.
Grigg J, Arnon S, Silverman M . Fractional processing of sequential bronchoalveolar lavage fluid from intubated babies. Eur Respir J. 1992; 5(6):727-32. View

3.
Wyllie A, KERR J, Currie A . Cell death: the significance of apoptosis. Int Rev Cytol. 1980; 68:251-306. DOI: 10.1016/s0074-7696(08)62312-8. View

4.
Merritt T, Cochrane C, Holcomb K, Bohl B, Hallman M, Strayer D . Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest. 1983; 72(2):656-66. PMC: 1129225. DOI: 10.1172/JCI111015. View

5.
Placzek M, Silverman M . Selective placement of bronchial suction catheters in intubated neonates. Arch Dis Child. 1983; 58(10):829-31. PMC: 1628299. DOI: 10.1136/adc.58.10.829. View